Stock listing

NASDAQ:REGN Regeneron Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Regeneron Pharmaceuticals, Inc.

Follow Regeneron Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:REGN

$920.69 USD -24.84 (-2.6%)

Close on Nov 20, 2026

Past year +24.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$916.66 – $948.42 USDNov 20, 2026
Volume
877,666 sharesNov 20, 2026
Market cap
$93.57B USDAt the close on Nov 20, 2026 · price × 101.6M shares outstanding
52-week range
$591.52 – $991.73 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$667.9M USDMedian day 682,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Regeneron Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:REGN · Home$920.69 USD-24.84 (-2.6%)877,666$936.37$948.42$916.66$945.53Close on Nov 20, 2026
B3:REGN3492.08 BRL-0.43 (-0.5%)14692.5193.7291.4492.51Close on Nov 19, 2026
Frankfurt:RGO€837.10 EUR-7.70 (-0.9%)26€839.10€839.10€837.10€844.80Close on Nov 20, 2026
LSE:0R2M$921.17 USD-9.465 (-1.0%)886$939.65$948.44$918.00$930.63Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:REGN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$920.69-24.84-2.6%$936.37$948.42$916.66877,666
$945.53-12.23-1.3%$957.25$972.00$943.26704,317
$957.76+5.36+0.6%$952.56$965.48$946.94928,098
$952.40-3.07-0.3%$964.00$971.67$947.89700,518
$955.47+4.28+0.4%$952.47$961.94$942.00927,985
$951.19-8.22-0.9%$971.85$981.55$944.711,028,860
$959.41+43.35+4.7%$904.99$961.98$899.001,220,674
$916.06-3.90-0.4%$915.34$919.72$905.38516,987
$919.96+15.61+1.7%$922.00$933.36$901.07854,548
$904.35+1.45+0.2%$887.22$911.57$887.221,119,227
$902.90-27.77-3.0%$938.51$948.06$901.591,398,322
$930.67-42.69-4.4%$989.90$991.73$927.421,383,132
$973.36+12.10+1.3%$956.28$975.49$953.001,198,080
$961.26+33.37+3.6%$927.22$974.00$927.001,660,934
$927.89+109.12+13.3%$869.43$935.34$839.082,851,725
$818.77+5.50+0.7%$826.14$828.19$811.63781,724
$813.27-2.83-0.3%$806.20$821.16$802.20533,560
$816.10+8.43+1.0%$807.67$816.14$804.17716,874
$807.67+2.65+0.3%$812.31$817.17$796.61418,085
$805.02-14.07-1.7%$819.09$819.09$801.22527,718
$819.09+13.42+1.7%$809.72$825.52$800.00852,286
$805.67-1.81-0.2%$806.74$813.86$800.24578,415
$807.48+25.44+3.3%$794.66$807.86$789.69619,494
$782.04-8.70-1.1%$792.59$800.00$780.83489,437
$790.74-5.60-0.7%$803.01$805.68$787.32653,500
$796.34+17.98+2.3%$802.33$809.49$792.58798,800
$778.36+25.24+3.4%$758.16$781.84$755.21878,400
$753.12-9.69-1.3%$762.49$765.60$743.57629,600
$762.81+16.27+2.2%$748.67$768.66$744.96618,200
$746.54+6.97+0.9%$737.20$751.27$732.83466,000
$739.57-2.55-0.3%$742.12$744.50$723.65500,300
$742.12+3.40+0.5%$738.05$753.68$734.18626,400
$738.72+12.25+1.7%$734.61$740.51$727.16615,100
$726.47-8.73-1.2%$734.37$736.42$722.02694,700
$735.20+0.39+0.1%$740.50$742.50$729.20613,900
$734.81-23.46-3.1%$766.53$777.43$726.021,042,800
$758.27+7.76+1.0%$749.84$763.72$742.94872,400
$750.51-1.74-0.2%$745.85$752.47$741.83804,300
$752.25-35.79-4.5%$778.09$780.95$750.001,149,800
$788.04-7.98-1.0%$803.87$803.87$784.13592,100
$796.02-5.80-0.7%$801.59$807.21$789.39602,600
$801.82-2.08-0.3%$805.23$813.53$790.02721,100
$803.90+5.73+0.7%$802.48$811.66$791.31600,200
$798.17+13.32+1.7%$786.03$801.44$779.96704,400
$784.85-4.60-0.6%$787.34$794.73$779.652,473,436
$789.45+14.84+1.9%$781.18$789.99$774.78702,816
$774.61+0.50+0.1%$775.82$779.98$771.80382,900
$774.11-19.63-2.5%$788.53$788.58$769.57540,600
$793.74+12.25+1.6%$791.98$798.84$779.45591,100
$781.49-11.77-1.5%$800.00$800.22$780.81444,000
$793.26-14.39-1.8%$794.36$806.14$792.00526,900
$807.65-2.66-0.3%$803.83$808.63$796.73621,400
$810.31-17.41-2.1%$814.36$821.17$799.42556,500
$827.72-15.75-1.9%$840.06$841.54$825.83561,100
$843.47-8.56-1.0%$858.19$859.34$837.63496,200
$852.03+28.21+3.4%$826.24$854.49$825.77749,400
$823.82+24.74+3.1%$808.86$824.63$804.32682,600
$799.08+4.89+0.6%$782.44$802.78$779.08894,100
$794.19-13.52-1.7%$809.40$809.40$789.08488,305
$807.71-7.08-0.9%$806.18$817.62$804.27766,800
$814.79-18.77-2.3%$827.78$831.67$814.70585,300
$833.56+5.06+0.6%$829.22$839.94$823.44505,400
$828.50-5.54-0.7%$834.51$834.70$823.40672,000
$834.04+7.40+0.9%$835.74$847.00$826.64786,800
$826.64-14.20-1.7%$831.70$840.82$826.05596,400
Ticker
NASDAQ:REGN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Regeneron Pharmaceuticals, Inc. news

Regeneron Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
71 in the last 12 months · 374 in all · newest Nov 19, 2026 · oldest 2020
Calls
32 calls with a replay · 32 with a transcript · latest Oct 30, 2026
Decks
64 decks · latest July 2026

Where Regeneron Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:REGN · Home listing · This pageNASDAQUnited StatesUSD
gettex:RGOgettexGermanyEUR
LS Exchange:881535LS ExchangeGermanyEUR
Tradegate:RGOTradegateGermanyEUR
BMV:REGNBMVMexicoMXN
B3:REGN34B3BrazilBRL
BOATS:REGNBOATSUnited StatesUSD
Frankfurt:RGOFrankfurtGermanyEUR
LSE:0R2MLSEUnited KingdomUSD
Lang & Schwarz:881535Lang & SchwarzGermanyEUR
Dusseldorf:RGODusseldorfGermanyEUR
VIE:REGNViennaAustriaEUR
BIVA:REGNBIVAMexicoMXN
Stuttgart:RGOStuttgartGermanyEUR
Milan:1REGNMilanItalyEUR
Munich:RGOMunichGermanyEUR
Turquoise:REGNNTurquoiseUnited KingdomUSD
Xetra:RGOXetraGermanyEUR
EUROTLX:4REGNEUROTLXItalyEUR
BX Swiss:RGOBX SwissSwitzerlandCHF
Hanover:RGOHanoverGermanyEUR
BVL:REGNUSBVLPeruPEN
Hamburg:RGOHamburgGermanyEUR

Valuation

P/E 19.4× against a median of 21.5×: 4th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$86.26B USD
P/E
19.4×
EV/sales
5.1×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.8×
Gross margin
Not reported
Operating margin
28.8%
Net margin
28.5%
Debt to equity
0.1×
Beta vs S&P 500
0.36

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Regeneron Pharmaceuticals, Inc. · NASDAQ:REGNUS$93.57BUS$86.26B19.4×5.1×n/a2.8×28.5%0.1×0.36
Amgen Inc. · NASDAQ:AMGNUS$235.6BUS$276.5B25.1×7.1×15.8×16.4×24.1%3.8×0.48
Gilead Sciences, Inc. · NASDAQ:GILDUS$206.4BUS$226.2Bn/a7.3×n/a15.8×−12.5%2.0×0.36
CSL Limited · ASX:CSLUS$62.67BUS$72.05Bn/a4.6×14.3×4.2×−16.4%0.7×n/a
Biogen Inc. · NASDAQ:BIIBUS$36.89BUS$42.88B106×4.2×n/a1.9×3.4%0.4×0.34
Genmab A/S · OMXCOP:GMABUS$31.30BUS$34.64B42.9×8.1×24.4×4.9×17.0%0.8×n/a
Insmed Incorporated · NASDAQ:INSMUS$31.01BUS$30.41Bn/a20.0×n/a42.7×−39.9%0.8×0.01
Roivant Sciences Ltd. · NASDAQ:ROIVUS$27.92BUS$23.82Bn/a580×n/a7.0×−838.2%0.0×1.00
Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNYUS$19.26BUS$15.68B7.3×n/an/a5.3×n/a0.0×0.58
Ascendis Pharma A/S · NASDAQ:ASNDUS$16.73BUS$16.15B17.1×12.2×61.1×10.0×73.5%0.3×0.49
Exelixis, Inc. · NASDAQ:EXELUS$15.77BUS$14.88B17.8×6.0×n/a8.6×35.4%0.0×0.69
Median of the othersUS$31.15BUS$32.52B21.5×7.3×20.1×7.8×3.4%0.6×0.49

Forecasts

15 strong buy · 4 buy · 9 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
984.96 USD · Analysts' mean
EPS, year to Dec 2026
69.01 · 25 analysts
Revenue, year to Dec 2026
18.81B · 25 analysts

Team and board

Officers

OfficerRole
Leonard S. SchleiferBoard co-Chair, President and Chief Executive Officer
Tony ColesChair and former CEO, Cerevel
Chris FenimoreExecutive Vice President, Finance and Chief Financial Officer
George D. YancopoulosBoard co-Chair, President and Chief Scientific Officer
George FraleySenior Vice President, Associate General Counsel
Joseph J. LaRosaExecutive Vice President, General Counsel and Secretary
Larry CourySenior Vice President, Associate General Counsel
Richard GluckseligSenior Vice President, Associate General Counsel & Assistant Secretary
Alexandra BowieRegeneron Investor Relations
Christina ChanCorporate Communications
Ilana YellenRegeneron Investor Relations
Kailey KilmartinRegeneron Investor Relations
Mark HudsonInvestor Relations
Ryan CroweSenior Vice President, Investor Relations & Strategic Analysis
Sharon ChenRegeneron Investor Relations
Andrew MurphyExecutive Vice President, Research and Co-Chief Scientific Officer
Benjamin YocumSenior Vice President, Manufacturing Operations
Brook JenningsSenior Vice President, Global Immunology Commercial Business Unit
Daniel Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply
Danilo VergeSenior Vice President, Global Medical Affairs
Diana HughesSenior Vice President, Global Patient Safety
Divya PathakSenior Vice President, Chief Artificial Intelligence Officer
John CalabroSenior Vice President, Internal Audit
Justin HolkoSenior Vice President, Global Oncology/Hematology Commercial Business Unit
Kerry ReinertsenSenior Vice President, Strategic Alliances
Kevin ClarkSenior Vice President, Global Ophthalmology Commercial Business Unit
L. Andres SirulnikSenior Vice President, Clinical Development Unit Head, Hematology
Mack MacKenzieSenior Vice President, Commercial and G&A Digital & Technology
Marion McCourtExecutive Vice President, Commercial
Matthew EverettSenior Vice President, Global Procurement
Melissa LoznerSenior Vice President, Chief Compliance Officer
Ned BraunsteinExecutive Vice President, Regulatory Affairs, Global Patient Safety & Development Quality
Rick HallSenior Vice President, Human Resources and Chief Human Resources Officer
Ryan SteinbergerExecutive Vice President, Chief Digital & Technology Officer
Zoran BerkovicSenior Vice President, Financial Planning and Analysis

Board

DirectorRole
Bonnie L. BasslerChair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University
Joseph L. GoldsteinProfessor of Molecular Genetics and Internal Medicine and Chair, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas
Michael S. BrownDistinguished Chair in Biomedical Sciences, Regental Professor of Molecular Genetics and Internal Medicine, and Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southweste
Tony ColesChair and former CEO, Cerevel
David SnowDirector

Events

Calls

CallWhenStatus
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings CallFri, Oct 30, 2026 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2026 Earnings CallThu, Jul 30, 2026 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2026 Earnings CallWed, Apr 29, 2026 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2025 Earnings CallFri, Jan 30, 2026 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings CallTue, Oct 28, 2025 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2025 Earnings CallFri, Aug 01, 2025 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2025 Earnings CallTue, Apr 29, 2025 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2024 Earnings CallTue, Feb 04, 2025 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2024 Earnings CallThu, Oct 31, 2024 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2024 Earnings CallThu, Aug 01, 2024 · 8:30 AM ETReplay
All 32 calls
CallWhenStatus
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2024 Earnings CallThu, May 02, 2024 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2023 Earnings CallFri, Feb 02, 2024 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2023 Earnings CallThu, Nov 02, 2023 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2023 Earnings CallThu, Aug 03, 2023 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2023 Earnings CallThu, May 04, 2023 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2022 Earnings CallFri, Feb 03, 2023 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2022 Earnings CallWed, Aug 03, 2022 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2022 Earnings CallWed, May 04, 2022 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2021 Earnings CallFri, Feb 04, 2022 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2021 Earnings CallThu, Nov 04, 2021 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2021 Earnings CallThu, May 06, 2021 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2020 Earnings CallFri, Feb 05, 2021 · 8:00 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2020 Earnings CallThu, Nov 05, 2020 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2020 Earnings CallWed, Aug 05, 2020 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2020 Earnings CallTue, May 05, 2020 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2019 Earnings CallThu, Feb 06, 2020 · 8:00 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2019 Earnings CallTue, Nov 05, 2019 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2019 Earnings CallTue, Aug 06, 2019 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 2019 Earnings CallTue, May 07, 2019 · 8:30 AM ETReplay
Regeneron Pharmaceuticals (NASDAQ:REGN) Q4 2018 Earnings CallWed, Feb 06, 2019 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 30, 2026 · Before open+13.3%
Q2 2026Jul 30, 2026 · Before open+6.2%
Q1 2026Apr 29, 2026 · Before open−6.2%
Q4 2025Jan 30, 2026 · Before open−1.1%
Q3 2025Oct 28, 2025 · Before open+11.8%
Q2 2025Aug 1, 2025 · Before open+2.5%
Q1 2025Apr 29, 2025 · Before open−6.9%
Q4 2024Feb 4, 2025 · Before open+4.5%
Q3 2024Oct 31, 2024 · Before open−9.2%
Q2 2024Aug 1, 2024 · Before open+1.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · Before open+3.8%
Q4 2023Feb 2, 2024 · Before open−1.3%
Q3 2023Nov 2, 2023 · Before open+3.5%
Q2 2023Aug 3, 2023 · Before open+5.4%
Q1 2023May 4, 2023 · Before open−6.1%
Q4 2022Feb 3, 2023 · Before open+4.3%
Q3 2022Nov 3, 2022 · Before open−0.2%
Q2 2022Aug 3, 2022 · Before open+5.9%
Q1 2022May 4, 2022 · Before open+0.1%
Q4 2021Feb 4, 2022 · Before open+0.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck34 slidesJuly 2026
Q1 2026 Earnings PresentationEarnings36 slidesApr 29, 2026
Investor Presentation (April 2026)Investor deck40 slidesApr 22, 2026
Technical Presentation (February 2026)Technical19 slidesFeb 7, 2026
Q4 2025 Earnings PresentationEarnings35 slidesJan 30, 2026
J.P. Morgan Healthcare Conference 2026Conference19 slidesJan 12, 2026
Shareholder Meeting (2026)Shareholder meeting24 slides2026
Investor Day (December 2025)Investor day31 slidesDec 10, 2025
Investor Day (November 2025)Investor day36 slidesNov 10, 2025
Investor Presentation (October 2025)Investor deck38 slidesOctober 2025
Show 50 decks
DeckKindSlidesDate
Q2 2025 Earnings PresentationEarnings37 slidesAug 1, 2025
Q1 2025 Earnings PresentationEarnings39 slidesApr 29, 2025
Q4 2024 Earnings PresentationEarnings41 slidesFeb 4, 2025
J.P. Morgan Healthcare Conference 2025Conference41 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings33 slidesOct 31, 2024
Q2 2024 Earnings PresentationEarnings32 slidesAug 1, 2024
Shareholder Meeting (June 2024)Shareholder meeting28 slidesJun 14, 2024
Q1 2024 Earnings PresentationEarnings32 slidesMay 2, 2024
Q4 2023 Earnings PresentationEarnings32 slidesFeb 2, 2024
Technical Presentation (February 2024)Technical22 slidesFebruary 2024
Q3 2023 Earnings PresentationEarnings31 slidesNov 2, 2023
Q2 2023 Earnings PresentationEarnings32 slidesAug 3, 2023
Q1 2023 Earnings PresentationEarnings31 slidesMay 4, 2023
Investor Presentation (February 2023)Investor deck31 slidesFebruary 2023
J.P. Morgan Healthcare Conference 2023Conference37 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck26 slidesNovember 2022
Investor Presentation (August 2022)Investor deck21 slidesAugust 2022
Shareholder Meeting (June 2022)Shareholder meeting20 slidesJun 10, 2022
Investor Presentation (February 2022)Investor deck23 slidesFebruary 2022
JP Morgan Healthcare Conference 2022Conference28 slidesJan 10, 2022
Investor Presentation (November 2021)Investor deck27 slidesNovember 2021
Investor Presentation (August 2021)Investor deck27 slidesAugust 2021
Investor Presentation (May 2021)Investor deck28 slidesMay 2021
Investor Presentation (February 2021)Investor deck28 slidesFebruary 2021
JP Morgan Healthcare Conference 2021Conference38 slidesJan 11, 2021
Investor Presentation (November 2020)Investor deck26 slidesNovember 2020
Investor Presentation (August 2020)Investor deck22 slidesAugust 2020
Investor Presentation (June 2020)Investor deck27 slidesJune 2020
Proxy Contest (April 2020)Proxy contest44 slidesApr 24, 2020
JP Morgan Healthcare Conference 2020Conference34 slidesJan 13, 2020
Investor Presentation (June 2019)Investor deck25 slidesJune 2019
Investor Presentation (March 2019)Investor deck26 slidesMarch 2019
Corporate Update (January 2019)Corporate update13 slidesJan 7, 2019
Corporate Update (January 2019)Corporate update28 slidesJan 7, 2019
Investor Presentation (September 2018)Investor deck35 slidesSeptember 2018
Investor Presentation (January 2018)Investor deck15 slidesJan 8, 2018
Investor Presentation (January 2018)Investor deck35 slidesJan 8, 2018
Investor Presentation (January 2017)Investor deck15 slidesJan 9, 2017
J.P. Morgan 34th Annual Healthcare Conference January 2016Conference31 slidesJan 12, 2016
Corporate Update (January 2016)Corporate update9 slidesJan 12, 2016

This page holds 50 of 64 decks. Open Decks

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue14.3B14.2B13.1B12.2B16.1B8.50B6.56B5.15B5.87B4.86B
Cost of revenue402.8M237.5M202.5M194.6M
Gross profit6.15B4.91B5.67B4.67B
Research and development5.85B5.13B4.44B3.59B2.86B2.65B2.45B1.47B2.08B2.05B
Selling, general and administrative2.70B2.95B2.63B2.12B1.82B1.35B1.34B1.13B1.32B1.18B
Operating income3.58B3.99B4.05B4.74B8.95B3.58B2.21B2.53B2.08B1.33B
Depreciation and amortization543.7M482.9M421.0M341.4M286.2M235.9M210.3M148.2M145.5M104.7M
EBITDA4.12B4.47B4.47B5.08B9.23B3.81B2.42B2.68B2.23B1.44B
Interest expense43.8M55.2M73.0M59.4M57.3M56.9M30.2M28.2M25.1M7.20M
Income before tax5.23B4.78B4.20B4.86B9.33B3.81B2.43B2.55B2.08B1.33B
Income tax725.8M367.3M245.7M520.4M1.25B297.2M313.3M109.1M880.0M434.3M
Net income4.50B4.41B3.95B4.34B8.08B3.51B2.12B2.44B1.20B895.5M
Earnings per share, basic43.0740.9037.0540.5176.4032.6519.3822.6511.278.55
Earnings per share, diluted41.4838.3434.7738.2271.9730.5218.4621.2910.347.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.12B2.49B2.73B3.11B2.89B2.19B1.62B1.47B812.7M535.2M
Short-term investments5.49B6.52B8.11B4.64B2.81B1.39B1.60B1.34B596.8M503.5M
Receivables5.74B6.21B5.67B5.33B6.04B4.11B2.10B1.72B1.54B1.34B
Inventory3.20B3.09B2.58B2.40B1.95B1.92B1.42B1.15B726.1M399.4M
Current assets18.0B18.7B19.5B15.9B14.0B9.78B7.69B6.45B4.33B3.18B
Property, plant and equipment3.48B3.22B2.89B2.58B2.36B2.08B
Total assets40.6B37.8B33.1B29.2B25.4B17.2B14.8B11.7B8.76B6.97B
Accounts payable939.0M789.5M606.6M589.2M564.0M475.5M418.1M218.2M178.2M
Current liabilities4.37B3.94B3.42B3.14B3.93B2.70B2.10B1.44B1.14B1.24B
Long-term debt1.99B1.98B1.98B1.98B1.98B1.98B0
Total debt1.99B1.98B1.98B1.98B1.98B1.98B0
Total liabilities9.30B8.41B7.11B6.55B6.67B6.14B3.72B2.98B2.62B2.52B
Shareholders' equity31.3B29.4B26.0B22.7B18.8B11.0B11.1B8.76B6.14B4.45B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations4.98B4.42B4.59B5.01B7.08B2.62B2.43B2.20B1.31B1.49B
Capital spending-898.4M-755.9M-718.6M-590.1M-551.9M-614.6M-429.6M-383.1M-272.6M-511.9M
Free cash flow4.08B3.66B3.88B4.42B6.53B2.00B2.00B1.81B1.03B974.0M
Cash from investing-629.1M-2.47B-3.19B-3.78B-5.38B-70.6M-2.03B-1.46B-1.01B-1.05B
Cash from financing-3.72B-2.20B-1.79B-1.01B-1.01B-1.97B-252.1M-77.1M-24.4M-700.5M
Dividends paid-370.3M00
Share buybacks-3.44B-2.60B-2.23B-2.08B-1.65B-5.85B-275.9M-4.40M00
Change in cash634.7M-248.8M-381.6M221.3M690.8M577.0M150.1M655.0M277.5M-261.4M

Open Financials

Filings

FilingDateTypeFiled with
S-8 · Registration statement for employee plansNov 19, 2026Offer documentSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
13F-HR · Fund holdings reportNov 5, 2026Fund holdings reportSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
144 · Notice of proposed saleOct 30, 2026Other filingsSEC
144 · Notice of proposed saleOct 30, 2026Other filingsSEC
144 · Notice of proposed saleOct 30, 2026Other filingsSEC
10-Q · Quarterly reportOct 30, 2026Quarterly reportSEC
8-K · Current reportOct 30, 2026ResultsSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
144 · Notice of proposed saleOct 14, 2026Other filingsSEC
8-K · Current reportOct 6, 2026ResultsSEC
8-K · Current reportSep 30, 2026Management or board changeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
N-PXAug 20, 2026Other filingsSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
13F-HR · Fund holdings reportAug 7, 2026Fund holdings reportSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJul 6, 2026ResultsSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
13F-HR · Fund holdings reportMay 8, 2026Fund holdings reportSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
10-Q · Quarterly reportApr 29, 2026Quarterly reportSEC
8-K · Current reportApr 29, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
8-K · Current reportApr 8, 2026ResultsSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
13F-HR · Fund holdings reportFeb 6, 2026Fund holdings reportSEC
10-K · Annual reportFeb 4, 2026Annual reportSEC
8-K · Current reportJan 30, 2026ResultsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
144 · Notice of proposed saleNov 7, 2025Other filingsSEC
13F-HR · Fund holdings reportNov 7, 2025Fund holdings reportSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
144 · Notice of proposed saleOct 29, 2025Other filingsSEC
10-Q · Quarterly reportOct 28, 2025Quarterly reportSEC
8-K · Current reportOct 28, 2025ResultsSEC
8-K · Current reportOct 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
13F-HR · Fund holdings reportAug 1, 2025Fund holdings reportSEC
10-Q · Quarterly reportAug 1, 2025Quarterly reportSEC
8-K · Current reportAug 1, 2025ResultsSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 5, 2025Big-stake noticeSEC
13F-HR · Fund holdings reportMay 2, 2025Fund holdings reportSEC
10-Q · Quarterly reportApr 29, 2025Quarterly reportSEC
8-K · Current reportApr 29, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 22, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECApr 17, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementApr 7, 2025Meeting noticeSEC
CORRESP · Letter to the SECApr 3, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 21, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
13F-HR · Fund holdings reportFeb 7, 2025Fund holdings reportSEC
10-K · Annual reportFeb 5, 2025Annual reportSEC
8-K · Current reportFeb 4, 2025ResultsSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
S-3ASR · Registration statementOct 31, 2024Offer documentSEC
10-Q · Quarterly reportOct 31, 2024Quarterly reportSEC
8-K · Current reportOct 31, 2024ResultsSEC
8-K · Current reportOct 7, 2024ResultsSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
144 · Notice of proposed saleOct 1, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 11, 2024Other filingsSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
144 · Notice of proposed saleSep 3, 2024Other filingsSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
144 · Notice of proposed saleAug 28, 2024Other filingsSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
4 · Change in ownershipAug 15, 2024Insider tradeSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
144 · Notice of proposed saleAug 14, 2024Other filingsSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
144 · Notice of proposed saleAug 8, 2024Other filingsSEC
4 · Change in ownershipAug 7, 2024Insider tradeSEC
144 · Notice of proposed saleAug 7, 2024Other filingsSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
144 · Notice of proposed saleAug 2, 2024Other filingsSEC
CORRESP · Letter to the SECAug 1, 2024Other filingsSEC
144 · Notice of proposed saleAug 1, 2024Other filingsSEC
144 · Notice of proposed saleAug 1, 2024Other filingsSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC

This page holds 200 of 1,003 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Regeneron Pharmaceuticals, Inc.’s releases

Common shares
101,630,713
Fully diluted
101,630,713

Fully diluted

LineShares
Common shares101,630,713

Share count over time

CountShares
Nov 22, 2026101,630,713

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard10.7M10.5%US$8.11BSep 30, 2026
BlackRock8.85M8.7%US$6.71BSep 30, 2026
State Street4.88M4.8%US$3.7BSep 30, 2026
Dodge & Cox4.77M4.7%US$3.62BSep 30, 2026
Invesco3.72M3.7%US$2.82BSep 30, 2026
JPMorgan3.31M3.3%US$2.48BSep 30, 2026
Franklin Templeton2.96M2.9%US$2.75BSep 30, 2026
Geode Capital2.63M2.6%US$1.99BSep 30, 2026
Nuveen1.96M1.9%US$1.48BSep 30, 2026
Loomis Sayles & Co L P1.72M1.7%US$1.3BSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Morgan Stanley1.37M1.4%US$1.04BSep 30, 2026
AQR Capital Management LLC1.31M1.3%US$979MSep 30, 2026
Wellington1.27M1.3%US$964MSep 30, 2026
Bank of America1.17M1.1%US$884MSep 30, 2026
Amundi1.15M1.1%US$873MSep 30, 2026
UBS1.1M1.1%US$838MSep 30, 2026
T. Rowe Price1.1M1.1%US$837MSep 30, 2026
Fidelity1.04M1.0%US$785MSep 30, 2026
Northern Trust998K0.98%US$756MSep 30, 2026
Capital Group876K0.86%US$664MSep 30, 2026
Two Sigma870K0.86%US$659MSep 30, 2026
First Trust827K0.81%US$627MSep 30, 2026
BNP Paribas803K0.79%US$609MSep 30, 2026
Schwab773K0.76%US$586MSep 30, 2026
BNY735K0.72%US$557MSep 30, 2026
Legal & General701K0.69%US$531MSep 30, 2026
Goldman Sachs694K0.68%US$526MSep 30, 2026
DWS687K0.68%US$521MSep 30, 2026
Dimensional610K0.60%US$462MSep 30, 2026
Nordea Investment Management AB600K0.59%US$451MSep 30, 2026
Allianz420K0.41%US$319MSep 30, 2026
Neuberger Berman Group LLC416K0.41%US$316MSep 30, 2026
Robeco Institutional Asset Management B.V.403K0.40%US$306MSep 30, 2026
Arrowstreet Capital, Limited Partnership396K0.39%US$300MSep 30, 2026
National Pension Service381K0.37%US$289MSep 30, 2026
HSBC358K0.35%US$271MSep 30, 2026
Citadel353K0.35%US$267MSep 30, 2026
MUFG351K0.35%US$266MSep 30, 2026
Barclays348K0.34%US$264MSep 30, 2026
AllianceBernstein300K0.30%US$227MSep 30, 2026
TD297K0.29%US$223MSep 30, 2026
Man Group plc295K0.29%US$224MSep 30, 2026
Worldquant Millennium Advisors LLC284K0.28%US$215MSep 30, 2026
Swiss National Bank282K0.28%US$214MSep 30, 2026
Bellevue Group AG280K0.28%US$212MSep 30, 2026
Federated Hermes, Inc.278K0.27%US$211MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.278K0.27%US$211MSep 30, 2026
Renaissance Technologies272K0.27%US$206MSep 30, 2026
Los Angeles Capital Management LLC266K0.26%US$202MSep 30, 2026
Lsv Asset Management246K0.24%US$187MSep 30, 2026

This page holds 50 of 1,407 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund3.27M3.2%US$2.04BJun 30, 2026
Dodge & Cox Stock Fund3.12M3.1%US$1.95BJun 30, 2026
Vanguard 500 Index Fund2.59M2.5%US$1.61BJun 30, 2026
Invesco QQQ Trust, Series 12.19M2.2%US$1.36BJun 30, 2026
iShares Core S&P 500 ETF1.37M1.4%US$857MJun 30, 2026
Fidelity 500 Index Fund1.29M1.3%US$793MMay 31, 2026
Putnam Large Cap Value Fund1.15M1.1%US$879MJul 31, 2026
Vanguard Mid-Cap Index Fund1.12M1.1%US$696MJun 30, 2026
Vanguard Health Care Fund1.07M1.1%US$818MJul 31, 2026
Vanguard Value Index Fund982K0.97%US$612MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
JPMorgan Equity Premium Income ETF753K0.74%US$469MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account727K0.72%US$454MJun 30, 2026
iShares Biotechnology ETF715K0.70%US$446MJun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF706K0.69%US$440MJun 30, 2026
College Retirement Equities Fund - Growth Account587K0.58%US$366MJun 30, 2026
Vanguard Institutional Index Fund542K0.53%US$338MJun 30, 2026
Loomis Sayles Growth Fund485K0.48%US$303MJun 30, 2026
New Perspective Fund468K0.46%US$292MJun 30, 2026
Invesco NASDAQ 100 ETF442K0.43%US$271MMay 31, 2026
First Trust Rising Dividend Achievers ETF334K0.33%US$208MJun 30, 2026
Pacer US Cash Cows 100 ETF333K0.33%US$254MJul 31, 2026
Vanguard Mid-Cap Value Index Fund331K0.33%US$206MJun 30, 2026
Vanguard Health Care Index Fund310K0.31%US$191MMay 31, 2026
Invesco S&P 500 Equal Weight ETF310K0.30%US$236MJul 31, 2026
Dodge & Cox Global Stock Fund300K0.29%US$187MJun 30, 2026
JPMorgan Nasdaq Equity Premium Income ETF248K0.24%US$155MJun 30, 2026
Putnam Focused Large Cap Value ETF240K0.24%US$147MMay 29, 2026
T. Rowe Price U.S. Large-Cap Core Fund, Inc.239K0.24%US$149MJun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 500(R) ETF238K0.23%US$149MJun 30, 2026
Dodge & Cox Balanced Fund238K0.23%US$148MJun 30, 2026
Invesco Comstock Fund227K0.22%US$173MJul 31, 2026
iShares Russell 1000 Value ETF226K0.22%US$141MJun 30, 2026
Schwab S&P 500 Index Fund223K0.22%US$170MJul 31, 2026
Strategic Advisers U.S. Total Stock Fund220K0.22%US$135MMay 31, 2026
Schwab U.S. Large-Cap Growth ETF215K0.21%US$132MMay 31, 2026
JPMorgan U.S. Equity Fund199K0.20%US$124MJun 30, 2026
Fidelity Total Market Index Fund191K0.19%US$117MMay 31, 2026
Growth Fund of America187K0.18%US$115MMay 31, 2026
Fidelity SAI U.S. Low Volatility Index Fund170K0.17%US$129MJul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF165K0.16%US$103MJun 30, 2026
iShares S&P 500 Value ETF164K0.16%US$102MJun 30, 2026
Bridge Builder Large Cap Value Fund154K0.15%US$96.3MJun 30, 2026
Fidelity Series Total Market Index Fund154K0.15%US$94.7MMay 31, 2026
Nuveen Large Cap Value Fund152K0.15%US$116MJul 31, 2026
WisdomTree U.S. Quality Dividend Growth Fund145K0.14%US$90.3MJun 30, 2026
JPMorgan Value Advantage Fund138K0.14%US$86MJun 30, 2026
Invesco Equity and Income Fund131K0.13%US$80.6MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF129K0.13%US$80.5MJun 30, 2026
The U.S. Large Cap Value Series123K0.12%US$93.9MJul 31, 2026
JPMorgan Hedged Equity Fund123K0.12%US$76.7MJun 30, 2026

This page holds 50 of 1,008 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Sing George L
Director
Sale176USD 956.96US$168KNov 17, 2026
Sing George L
Director
Sale359USD 957.49US$344KNov 17, 2026
Sing George L
Director
Sale465USD 958.11US$446KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale346USD 956.70US$331KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale202USD 957.53US$193KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale244USD 958.27US$234KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale506USD 959.45US$485KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale257USD 960.65US$247KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale584USD 961.45US$561KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale295USD 962.70US$284KNov 17, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale255USD 963.60US$246KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale340USD 964.36US$328KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale93USD 949.69US$88,321Nov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale74USD 950.61US$70,345Nov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale298USD 951.75US$284KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale220USD 952.75US$210KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale671USD 953.69US$640KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale313USD 954.45US$299KNov 17, 2026
Murphy Andrew J
Officer: Co-Chief Scientific Officer
Sale313USD 955.48US$299KNov 17, 2026
Sing George L
Director
Sale1,000USD 960.26US$960KNov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale44USD 952.79US$41,923Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale42USD 963.70US$40,475Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale21USD 964.69US$20,258Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale63USD 965.62US$60,834Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale26USD 971.93US$25,270Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale59USD 954.46US$56,313Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale30USD 955.51US$28,665Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale22USD 956.01US$21,032Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale44USD 958.47US$42,173Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale66USD 959.46US$63,324Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale49USD 960.31US$47,055Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale59USD 961.36US$56,720Nov 16, 2026
McCourt Marion
Officer: EVP Commercial
Sale41USD 962.44US$39,460Nov 16, 2026
Pitofsky Jason
Officer: SVP Controller
Sale35USD 945.61US$33,096Nov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale179USD 950.76US$170KNov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale439USD 939.57US$412KNov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale575USD 940.46US$541KNov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale982USD 941.58US$925KNov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale1,215USD 942.31US$1.14MNov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale529USD 943.53US$499KNov 4, 2026
Pitofsky Jason
Officer: SVP Controller
Sale108USD 944.22US$102KNov 4, 2026
Zoghbi Huda Y
Director
Sale6,939USD 970.42US$6.73MNov 3, 2026
Zoghbi Huda Y
Director
Sale500USD 971.06US$486KNov 3, 2026
Poon Christine A
Director
Sale218USD 966.74US$211KNov 2, 2026
Poon Christine A
Director
Sale772USD 967.38US$747KNov 2, 2026
Poon Christine A
Director
Sale2,499USD 968.58US$2.42MNov 2, 2026
Poon Christine A
Director
Sale3,203USD 969.50US$3.11MNov 2, 2026
Poon Christine A
Director
Sale937USD 970.51US$909KNov 2, 2026
Poon Christine A
Director
Sale201USD 971.31US$195KNov 2, 2026
Sing George L
Director
Sale1,040USD 967.07US$1.01MNov 2, 2026

This page holds 50 of 117 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Vanguard Capital Management LLC7.37%7.66MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Alexander Ingram
Other companies: Black Diamond Therapeutics, Inc. (Director · Sep 25, 2020 – Sep 16, 2022 · Past); Novan Inc (Director · Sep 20, 2016 – Jul 28, 2020 · Past); BioCryst Pharmaceuticals, Inc. (Director · Aug 5, 2015 – Feb 28, 2023 · Past); Pharmaceutical Product Development Inc (Director · May 18, 2011 – Dec 5, 2011 · Past); Bausch Health Companies Inc. (Director · Sep 28, 2010 – Mar 31, 2017 · Past); Wolfspeed, Inc. (Director · Dec 29, 2008 – Oct 17, 2018 · Past); Edwards Lifesciences Corporation (Director · May 12, 2006 – May 15, 2015 · Past); Osi Pharmaceuticals Inc (Director · Mar 16, 2006 – Jun 8, 2010 · Past); Valeant Pharmaceuticals International Inc (Director · Jan 1, 2006 – Sep 28, 2010 · Past); Lowe's Companies, Inc. (Director · Dec 31, 2005 – Mar 31, 2011 · Past); Nortel Networks Corporation (USA) (Director · Dec 30, 2005 – Mar 31, 2006 · Past)
Director · Apr 4, 2014 – May 22, 2015 · Past
David Schenkein
Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Foundation Medicine Inc (Director · Sep 24, 2013 – Jun 16, 2016 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Jun 20, 2024 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Jun 18, 2020 · Past); Foghorn Therapeutics Inc. (General Partner, Co-leader, Agios · Until Apr 13, 2026 · Past)
Director · Since at least Sep 8, 2023
Bonnie Bassler
Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 22, 2021); Royalty Pharma plc (Board Member · Since at least Jun 15, 2020); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past)
Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University · Since at least Sep 9, 2016
Murray A Goldberg
Other companies: Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Teva Pharmaceutical Industries Limited (Director · Jan 1, 2018 – Jun 11, 2019 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – May 18, 2020 · Past)
SVP Administration & Asst Secr · Jan 9, 2006 – Dec 16, 2014 · Past
Robert E. Landry
Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 5, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Cytokinetics, Incorporated (Director · Since at least Feb 10, 2025)
EVP Finance CFO · Mar 31, 2022 – Feb 2, 2024 · Past
Tony Coles
Other companies: Kineta Inc. (Executive Chair, Director · Dec 22, 2020 – Apr 1, 2021 · Past); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); McKesson Corporation (Director · Jul 25, 2018 – Aug 17, 2020 · Past)
Director · Since at least Jan 2, 2018
Christine A. Poon
Other companies: Neurocrine Biosciences, Inc. (Director · Since at least Apr 15, 2026); Prudential Financial, Inc. (Director · Since at least Mar 26, 2026)
Director · Since at least Nov 2, 2026
Craig B Thompson
Other companies: Charles River Laboratories International, Inc. (Director · Since at least Dec 3, 2013); Merck & Company, Inc. (Director · Dec 1, 2008 – May 25, 2018 · Past)
Director · Since at least Oct 3, 2022
Charles A Baker
Other companies: Progenics Pharmaceuticals Inc (Director · Jul 3, 2006 – Jun 13, 2012 · Past)
Director · Jan 3, 2006 – Jan 2, 2018 · Past
Marc Tessier-Lavigne
Other companies: Denali Therapeutics Inc. (Director · Since at least May 30, 2019)
Director · Jan 2, 2020 – Jan 3, 2023 · Past
All 56 people
PersonSeat
Michael S. Brown
Other companies: Pfizer, Inc. (Director · Apr 27, 2006 – Apr 28, 2011 · Past)
Distinguished Chair in Biomedical Sciences, Regental Professor of Molecular Genetics and Internal Medicine, and Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southweste · Since at least Jan 3, 2006
Alexandra BowieRegeneron Investor Relations · Since at least Oct 1, 2026
Andrew MurphyExecutive Vice President, Research and Co-Chief Scientific Officer · Since at least Dec 11, 2019
Arthur F RyanDirector · Since at least Apr 1, 2026
Benjamin YocumSenior Vice President, Manufacturing Operations · Since at least Nov 4, 2026
Brook JenningsSenior Vice President, Global Immunology Commercial Business Unit · Since at least Nov 4, 2026
Chris FenimoreExecutive Vice President, Finance and Chief Financial Officer · Since at least Nov 4, 2026
Christina ChanCorporate Communications · Since at least Sep 24, 2026
Christopher R FenimoreEVP Finance CFO · Since at least Mar 2, 2017
Daniel Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply · Since at least Apr 22, 2025
Danilo VergeSenior Vice President, Global Medical Affairs · Since at least Nov 4, 2026
David SnowDirector · Since at least Feb 23, 2026
Diana HughesSenior Vice President, Global Patient Safety · Since at least Nov 4, 2026
Divya PathakSenior Vice President, Chief Artificial Intelligence Officer · Since at least Nov 4, 2026
Eric M ShooterDirector · Jan 2, 2009 – Feb 12, 2014 · Past
George D. YancopoulosBoard co-Chair, President and Chief Scientific Officer · Since at least Oct 30, 2015
George FraleySenior Vice President, Associate General Counsel · Since at least Nov 4, 2026
George L SingDirector · Since at least Jan 2, 2024
Huda Y ZoghbiDirector · Since at least Jan 2, 2020
Ilana YellenRegeneron Investor Relations · Since at least Feb 27, 2026
Jason PitofskySVP Controller · Since at least Nov 7, 2025
John CalabroSenior Vice President, Internal Audit · Since at least Nov 4, 2026
Joseph J. LaRosaExecutive Vice President, General Counsel and Secretary · Since at least Dec 16, 2011
Joseph L. GoldsteinProfessor of Molecular Genetics and Internal Medicine and Chair, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas · Since at least Mar 30, 2022
Justin HolkoSenior Vice President, Global Oncology/Hematology Commercial Business Unit · Since at least Nov 4, 2026
Kailey KilmartinRegeneron Investor Relations · Since at least Mar 24, 2026
Kathryn GuariniDirector · Since at least Sep 8, 2023
Kerry ReinertsenSenior Vice President, Strategic Alliances · Since at least Nov 4, 2026
Kevin ClarkSenior Vice President, Global Ophthalmology Commercial Business Unit · Since at least Nov 4, 2026
L. Andres SirulnikSenior Vice President, Clinical Development Unit Head, Hematology · Since at least Nov 13, 2025
Larry CourySenior Vice President, Associate General Counsel · Since at least Nov 4, 2026
Leonard S. SchleiferBoard co-Chair, President and Chief Executive Officer · Since at least Mar 6, 2006
Mack MacKenzieSenior Vice President, Commercial and G&A Digital & Technology · Since at least Nov 4, 2026
Marion McCourtExecutive Vice President, Commercial · Since at least Apr 1, 2022
Mark HudsonInvestor Relations · Since at least Oct 25, 2026
Matthew EverettSenior Vice President, Global Procurement · Since at least Nov 4, 2026
Melissa LoznerSenior Vice President, Chief Compliance Officer · Since at least Nov 4, 2026
Ned BraunsteinExecutive Vice President, Regulatory Affairs, Global Patient Safety & Development Quality · Since at least Nov 4, 2026
Neil StahlEVP Research and Development · Dec 9, 2020 – Dec 16, 2024 · Past
P Roy VagelosDirector · Mar 30, 2022 – Apr 3, 2023 · Past
Richard GluckseligSenior Vice President, Associate General Counsel & Assistant Secretary · Since at least Nov 4, 2026
Rick HallSenior Vice President, Human Resources and Chief Human Resources Officer · Since at least Nov 4, 2026
Ryan CroweSenior Vice President, Investor Relations & Strategic Analysis · Since at least Nov 2, 2026
Ryan SteinbergerExecutive Vice President, Chief Digital & Technology Officer · Since at least Nov 5, 2026
Sharon ChenRegeneron Investor Relations · Since at least Dec 23, 2025
Zoran BerkovicSenior Vice President, Financial Planning and Analysis · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Regeneron Pharmaceuticals, Inc.